BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Boehringer Ingelheim Vetmedica, Inc. Expands Sales Force; Adds 75 New Positions


9/26/2012 6:59:13 AM

ST. JOSEPH, Mo., Sept. 25, 2012 /PRNewswire/ -- Boehringer Ingelheim Vetmedica, Inc. (BIVI), announces the addition of more than 75 positions to its U.S. sales force. The expanding animal health company plans to have all sales representatives and professional service veterinarians on board by early January 2013. The addition increases the entire BIVI field force to more than 350.

(Logo: http://photos.prnewswire.com/prnh/20120925/CG80722LOGO)

The increased sales force will help BIVI continue to support its expanding product lines as well as meet the needs of customers across all market segments.

"Our decision to increase the number of sales representatives in the field was made for the benefit of our customers," says Tim Bettington, vice president sales and marketing, BIVI. "We are continuing to grow as a company and we wouldn't be able to do that if it weren't for the loyalty of our customers. The additional representatives will allow us to work directly with more customers, creating more opportunity to meet their needs."

Since BIVI's acquisition of certain Fort Dodge Animal Health assets in 2009, the company has nearly doubled in size, both in terms of product offerings and number of employees. Dr. Albrecht Kissel, president and CEO, adds that it is BIVI's drive for innovation that continues to fuel the business growth.

"We are dedicated to our customers and the animal health industry," says Kissel. "Not only do we want to ensure we are developing technological innovations with our products, but also that we are providing the best customer service."

Bettington adds that expansion of the sales force is indicative of the value BIVI sees in customer relationships.

"By increasing the number of representatives we have in the field, we are increasing our ability to engage customers, provide innovative solutions and assist in the pursuit of delivering the best medicine," says Bettington.

BIVI plans to post positions during the fourth quarter of 2012. For more information about Boehringer Ingelheim Vetmedica, Inc. careers visit www.bi-vetmedica.com/careers.html

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability, are intrinsic factors in all of Boehringer Ingelheim's endeavours.

In 2011, Boehringer Ingelheim achieved net sales of about $17.1 billion (13.2 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 23.5 percent of its net sales.

For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.

SOURCE Boehringer Ingelheim Vetmedica, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES